<DOC>
	<DOCNO>NCT00743678</DOCNO>
	<brief_summary>An innovative therapeutic strategy increase complete resection rate utmost importance order enhance survival colorectal cancer patient unresectable liver-only metastasis . Therefore , investigator propose prospective study neoadjuvant chemotherapy use FOLFOX6 plus cetuximab convert initially unresectable liver metastasis potentially resectable disease .</brief_summary>
	<brief_title>Neoadjuvant FOLFOX6 + Cetuximab Patients With Colorectal Cancer Unresectable Liver Metastasis</brief_title>
	<detailed_description>We include patient unresectable liver-only metastatic disease independent EGFR status . The result study show resection rate neoadjuvant treatment patient colorectal cancer liver-only metastasis . Restaging include CT # 3 , # 6 , # 9 , # 12 cycle FOLFOX + Cetuximab If time , patient PD , Off-study SD , Continue study treatment resectable , # 12 cycle , PD , toxicities PR , If resectable , go surgery : resection liver metastasis primary tumor , present If unresectable , continue resectable , # 12 cycle , PD , toxicities Overall , total 12 cycle treatment include neoadjuvant therapy give either , without surgery . CT scan perform every 3 cycle first 12 cycle ( 6 month ) . After , CT scan perform every 2 month another 6 month , every 3 month 6 month , year earlier PD probable . AEs evaluate every cycle CT evaluation visit.. Patients undergo R1 resection unable get surgery , evaluate regularly PD . Radiofrequency ablation ( RFA ) may allow palliative local therapy patient suitable . RFA consider equal resection .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically proven colorectal cancer metastatic lesion ( ) liver ( ) unresectable Age ≥ 18 ECOG performance 0 1 Adequate organ function ( ( hepatic transaminase ≤ 5x upper limit normal , bilirubin &lt; 2.0 x upper limit normal , creatinine ≤ 1.5x upper limit normal , platelet &gt; 100,000/ul , absolute neutrophil count ≥ 1,500/ul ) At least one measurable lesion RECIST criterion Written inform consent Resectable liver metastasis Extrahepatic metastasis , regardless resectability Chronic active hepatitis cirrhosis Prior therapy metastatic disease Pregnant lactate woman Uncontrolled medical illness include medically uncontrolled infection , uncontrolled hypertension , unstable angina , symptomatic congestive heart failure , myocardial infarction within 6 month Previous adjuvant FOLFOX chemotherapy Prior adjuvant chemotherapy , administer within 6 month study entry Known hypersensitivity reaction component study treatment Prior agent direct EGFR Prior allergic reaction ( know sensitivity ) chimerized murine monoclonal antibody therapy Known alcohol drug abuse Participation another clinical study within 30 day registration Peripheral neuropathy &gt; grade 1 Other previous malignancy exception history previous curatively treat basal cell carcinoma skin preinvasive carcinoma cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Unresectable liver metastasis</keyword>
	<keyword>FOLFOX6</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Neoadjuvant therapy</keyword>
</DOC>